Morning Briefing
Summaries of health policy coverage from major news organizations
Amgen Expected To Enter A Guilty Plea To Unspecified Charges
The biotech giant is expected to plead guilty in a New York federal court criminal case. Some reports suggest the charges relate to "misbranding" -- which refers to the promotion of drugs for uses that have not gained the Food and Drug Administration's approval.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
